Saturn V Capital Management LP 13F holdings, Q3 2025
Holdings as of September 30, 2025 · filings on SEC EDGAR · latest filing →
Saturn V Capital Management LP disclosed 17 US equity positions worth $456.0m in its Q3 2025 13F filing. The largest position was ABVX at 14.9% of the reported book, followed by AMLX and JAZZ. Against the Q2 2025 filing, it opened 2 new positions, added to 8 and reduced 7 among the top 17 holdings.
What did Saturn V Capital Management LP own in Q3 2025? Top 17 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2025 |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | 14.9% | $68.0m | 801,224 | 29% | added | |
| 2 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 13.7% | $62.6m | 4,604,878 | 41% | added |
| 3 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 8.7% | $39.6m | 300,610 | 45% | added |
| 4 | DYN DYNE THERAPEUTICS INC | Healthcare | 7.4% | $33.8m | 2,674,469 | 84% | added |
| 5 | COGT COGENT BIOSCIENCES INC | Healthcare | 6.4% | $29.1m | 2,025,041 | -12% | reduced |
| 6 | PCVX VAXCYTE INC | Healthcare | 6.2% | $28.4m | 788,441 | 45% | added |
| 7 | CELC CELCUITY INC | Healthcare | 5.1% | $23.4m | 473,828 | -60% | reduced |
| 8 | CGON CG ONCOLOGY INC | Healthcare | 5.1% | $23.4m | 579,895 | -1% | reduced |
| 9 | IRON DISC MEDICINE INC | Healthcare | 4.9% | $22.5m | 340,897 | -14% | reduced |
| 10 | PHVS PHARVARIS N V | 4.8% | $22.1m | 886,332 | – | new | |
| 11 | XENE XENON PHARMACEUTICALS INC | Healthcare | 4.4% | $20.2m | 503,701 | 8% | added |
| 12 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.9% | $17.8m | 734,539 | -7% | reduced | |
| 13 | MERUS N V | 3.8% | $17.3m | 184,135 | -18% | reduced | |
| 14 | LENZ LENZ THERAPEUTICS INC | Healthcare | 3.8% | $17.1m | 368,176 | 8% | added |
| 15 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 3.0% | $13.5m | 1,151,686 | 58% | added |
| 16 | MNPR MONOPAR THERAPEUTICS INC | 2.8% | $12.7m | 155,370 | – | new | |
| 17 | NEWAMSTERDAM PHARMA COMPANY | 1.0% | $4.4m | 153,147 | -31% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.